The German biotech company Curevac was one of the hopes for the world about a year ago: Like Biontech and Moderna, it wanted to quickly develop a vaccine against the coronavirus.
At the beginning of summer 2021 one has to state: While Biontech has matured into a world star, Curevac stands for a botched opportunity of the century.
What are the reasons for this and what can be learned from it? What role does the German billionaire, entrepreneur and patron Dietmar Hopp play in this? And why could the Curevac case still help the German biotech industry? The mm editors Dietmar Palan, Martin Noé and Sven Clausen discuss this in this podcast.
